Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 18, 2017 - Issue sup1: Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis (ALS). Guest Editor: Angela Genge
Submit an article Journal homepage
3,964
Views
21
CrossRef citations to date
0
Altmetric
Research Article

Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis

Koji TakeiMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and Correspondence[email protected]
,
Fumihiro TakahashiMitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan
,
Shawn LiuMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Kikumi TsudaMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
&
Joseph PalumboMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and ;Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan
Pages 49-54 | Received 01 May 2017, Accepted 19 Jul 2017, Published online: 05 Sep 2017

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.